glp 1 taste change Glucagon-Like Peptide and Perception: From Molecular Mechanisms to Potential Clinical Implications When Favorites Fade: Navigating Taste

Medicines and Healthcare products Regulatory Agency (MHRA)

References: A Brave New World: Therapeutic Area Deep Dives on Obesity This blog is part of a new series exploring a range of topics in the obesity market, including: market size and scope, impact of payer controls, activity in non-traditional channels, patient behavior, GLP-1 impact, HCP responses, the policy landscape, pharmacy economics, and the outlook for the future of GLP-1

GLP-1 receptor agonists, such as semaglutide and liraglutide, are primarily used to manage type 2 diabetes and have been shown to aid in weight loss

In participants with type 2 diabetes, treatment resulted in HbA1c reductions up to 2.2% at 36 weeks, with mean reductions of 1.24% across pooled analyses

Monitor for gastrointestinal side effects that could affect medication adherence, maintain hydration, and remain vigilant for bleeding symptoms requiring prompt medical attention

GLP-1 can act on the central GLP-1 receptors (especially the hypothalamus) and the central satiety center, causing a feeling of satiety and reducing food intake, thus achieving weight loss through appetite suppression